阴极经颅直流电刺激治疗急性缺血性卒中:试点随机对照试验
STICA试点试验在45例接受再通治疗的急性大脑中动脉卒中患者中,评估阴极经颅直流电刺激(C-tDCS)对比假刺激的安全性和可行性。主要终点24小时梗死增长无显著组间差异,但C-tDCS组呈现梗死增长较小的趋势,尤其在中重度卒中和大血管闭塞亚组。
要点
- C-tDCS在急性卒中再通治疗中可行且耐受性良好,无严重不良事件。
- 全组及各亚组主要和次要终点均无显著差异,但C-tDCS组梗死增长呈较小趋势。
- 中重度卒中(NIHSS>10)或大血管闭塞患者可能从C-tDCS中获益,需进一步随机试验验证。
核心结论
- C-tDCS可行且耐受性良好,但活性组与假刺激组在任何终点上均无显著差异。
- 数据提示C-tDCS对NIHSS>10或大血管闭塞患者可能有潜在获益。
研究设计与样本
- STICA为单中心、双盲、两臂1:1随机对照试点试验,评估C-tDCS对比假刺激的安全性、可行性和疗效。
- 纳入45例适合再通治疗的急性大脑中动脉卒中患者,入院和24小时后均行磁共振成像。
主要发现
- 磁共振成像至C-tDCS开始的中位时间为45分钟,所有患者在再通手术完成前即开始C-tDCS。
- 全组未调整中位梗死增长差异为−2.2 mL(95%CI −12.2至1.5)。
- 中重度卒中亚组梗死增长差异为−5.7 mL(95%CI −21.6至2.6),大血管闭塞亚组为−7.7 mL(95%CI −24.2至2.6)。
- 主要终点24小时梗死增长及次要终点(第7天与入院NIHSS评分差、3个月改良Rankin量表评分)均无显著组间差异。
关键数值与推荐
- 主要终点为24小时梗死增长。
- 次要终点为第7天与入院NIHSS评分差和3个月改良Rankin量表评分。
- 基于观察到的效应量及标准α=5%、β=20%,未来针对NIHSS>10或大血管闭塞患者的试验估计样本量分别为102例和86例。
临床怎么用
- C-tDCS可在再通治疗过程中启动,未出现重大不良效应,支持进一步开展针对特定卒中人群的随机试验。
局限性
- 本研究为单中心试点试验,样本量小(45例),结果需在更大规模试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: In acute stroke, preventing infarct growth until complete recanalization occurs is a promising approach as an adjunct to reperfusion therapies to reduce infarct size and improve outcome. In rodent models, cathodal transcranial direct current stimulation (C-tDCS) decreases peri-infarct depolarizations and reduces infarct volume. We hypothesized that C-tDCS would nonpharmacologically reduce infarct growth in hyperacute middle cerebral artery territory stroke patients receiving reperfusion therapy. METHODS: STICA (Cathodal Transcranial Direct Stimulation in Acute Middle Cerebral Artery Stroke) was a pilot single-center, double-blind, 2-arms 1:1 randomized trial evaluating the safety, feasibility, and efficacy of C-tDCS versus sham stimulation in patients eligible for recanalization therapies. Magnetic resonance imaging was obtained both on admission and 24 hours later. The primary end point was 24-hour infarct growth. Secondary outcomes were (1) National Institutes of Health Stroke Scale score difference between day 7 and admission and (2) 3-month modified Rankin Scale score. RESULTS: Forty-five patients were randomized. Median magnetic resonance imaging-to-C-tDCS start time was 45 minutes; C-tDCS was started before completion of recanalization procedure in all patients. The intervention proved feasible in all patients. No major adverse effects occurred in either group. There was no significant difference between active and sham groups for any end point. However, an apparent trend towards smaller infarct growth in the C-tDCS arm was observed in the whole group (unadjusted median difference [IC95%]: −2.2 mL [−12.2 to 1.5]) and in the prespecified subsamples with moderate-to-severe stroke and large vessel occlusion (−5.7 mL [−21.6 to 2.6] and −7.7 mL [−24.2 to 2.6], respectively). CONCLUSIONS: C-tDCS was feasible and well tolerated. No significant difference was found between the active and sham groups. However, the data suggest potential benefits of C-tDCS in patients with National Institutes of Health Stroke Scale score of >10 or large vessel occlusion. Using the observed effect size and standard α=5% and β=20%, samples of 102 and 86, respectively, can be estimated for future trials in patients with these characteristics. Randomized trials particularly targeting these populations may be warranted.
引用
- Pruvost-Robieux E, Benzakoun J, Turc G, et al. Cathodal Transcranial Direct Current Stimulation in Acute Ischemic Stroke: Pilot Randomized Controlled Trial. Stroke. 2021. PMID: 33866820. doi:10.1161/STROKEAHA.120.032056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。